PRC
RIGL icon

Platte River Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Platte River Capital’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,290
Closed -$202K – 141
2015
Q2 		$202K Sell
6,290
-2,800
-31% -$107K 0.1% 150
2015
Q1 		$325K Sell
9,090
-750
-8% -$20.6K 0.15% 127
2014
Q4 		$223K Buy
9,840
+50
+0.5% +$1.01K 0.08% 153
2014
Q3 		$190K Buy
+9,790
New +$277K 0.05% 170

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Platte River Capital's RIGL Position: Q3 2015 in Review

Platte River Capital sold out of Rigel Pharmaceuticals (RIGL) in Q3 2015, closing a stake of 6,290 shares — an estimated $202K sold.

Platte River Capital first reported a position in RIGL in Q3 2014 and held it in 4 quarters. The position peaked at $325K in Q1 2015. 122 funds tracked by Wall St. Rank hold RIGL as of Q3 2015.

  • Platte River Capital reported no remaining Rigel Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Platte River Capital sold 6,290 Rigel Pharmaceuticals shares in Q3 2015, an estimated $202K.
  • Platte River Capital first reported a position in Rigel Pharmaceuticals in Q3 2014 and held it in 4 quarters.
  • Platte River Capital's Rigel Pharmaceuticals position peaked at $325K in Q1 2015.
  • 122 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2015.

Based on Platte River Capital's 13F filing for Q3 2015, filed 12 Nov 2015.